A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

• Status: Not yet recruiting
• Trial end date: 2026-04-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Klus Pharma Inc.
• Collaborator: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
• Treatments: Carboplatin; Osimertinib; Pembrolizumab

Criteria

Inclusion Criteria

1. Subjects must be at least 18 years of age on day of signing informed consent, regardless of gender;

2. Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC ;

3. Subjects for NSCLC should be confirmed to be EGFR (Epidermal growth factor receptor) wild-type and ALK (Anaplastic lymphoma kinase) fusion gene negative; or confirmed to harbor EGFR mutation;

4. Locally advanced or metastatic NSCLC subjects without actionable EGFR mutations and ALK fusion genes, no prior systemic treatment; subjects with EGFR mutation, no prior systemic treatment or failed prior EGFR-TKI (Tyrosine kinase inhibitor) treatment;

5. Subjects are able to provide tumor blocks or slides before the first dose of study intervention;

6. Subject must have at least one radiographically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria;

7. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1;

8. Life expectancy at least 3 months for the subject;

9. Adequate organ function;

10. Subjects must have recovered from all toxicities led by prior treatment;

11. Contraceptive methods used by male and female subjects must comply with contraceptive methods of local regulations for clinical study subjects;

12. Subjects should voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.

Exclusion Criteria

1. Subjects with mixed SCLC histopathological features;

2. Subjects with a known history of prior malignancy;

3. Subjects with known meningeal metastases, brainstem metastases, spinal cord metastases and/or compression, or active central nervous system (CNS) metastases;

4. Subjects with ≥ Grade 2 peripheral neuropathy;

5. Subjects who had arteriovenous thromboembolic events;

6. Subjects with active inflammatory bowel disease or previous clear history of inflammatory bowel disease;

7. Subjects who suffer from cardiovascular diseases of clinical significance;

8. Subjects with a history of interstitial lung disease (ILD)/non-infectious pneumonitis that required steroids;

9. Subjects with uncontrolled systemic disease as judged by the Investigator;

10. Subjects with active autoimmune disease that required systemic treatment in the past 2 years;

11. Subjects with active hepatitis B or hepatitis C;

12. Subjects with known history of Human Immunodeficiency Virus (HIV)

13. Subjects with known active tuberculosis;

14. Subjects with known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;

15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study;

16. Subjects whose condition deteriorated rapidly, such as severe changes in performance status, during the screening process prior to the first dose of study intervention;

17. Subjects with other circumstances that, in the opinion of the Investigator, are not appropriate for participation in this study.